Moderna Settles COVID Vaccine Patent Case for $2.25B

Moderna Finalizes Major Patent Settlement

Moderna has agreed to a settlement of up to $2.25 billion with Genevant Sciences and Arbutus Biopharma, resolving a significant legal dispute over the lipid nanoparticle LNP technology used in its COVID-19 vaccine. The agreement eliminates future royalty risks for this specific technology.

Details of the Agreement

The settlement includes an upfront payment of $950 million scheduled for July 2026. An additional $1.3 billion is contingent on the outcome of a separate legal appeal. This deal concludes all ongoing U.S. and international lawsuits accusing Moderna of using the patented LNP delivery system without authorization.

Market Reaction and Financial Implications

Following the announcement, Moderna's shares surged over 10% in after-hours trading, with Arbutus shares also climbing 11%. Analysts view the settlement positively, as it removes the uncertainty of potentially higher royalty payments. The total payment represents a small fraction of Moderna's approximately $48 billion in global vaccine sales.

Conclusion and Broader Context

This settlement resolves a key legal challenge for Moderna, allowing the company to move forward without the risk of ongoing royalties on its current and upcoming COVID-related vaccines. The broader landscape of COVID-19 vaccine patent litigation continues, with similar lawsuits involving major pharmaceutical companies like Pfizer and BioNTech still pending.

FAQ

Q: What technology was at the center of the dispute?
A: The dispute was over lipid nanoparticle or LNP technology, a crucial delivery system that protects mRNA molecules in vaccines.

Q: How much will Moderna pay upfront?
A: Moderna will make an upfront payment of $950 million in July 2026.

Source: Investing.com